These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23803726)

  • 1. Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155.
    Litvinov IV; Pehr K; Sasseville D
    Cell Cycle; 2013 Jul; 12(14):2172-3. PubMed ID: 23803726
    [No Abstract]   [Full Text] [Related]  

  • 2. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.
    Kopp KL; Ralfkiaer U; Gjerdrum LM; Helvad R; Pedersen IH; Litman T; Jønson L; Hagedorn PH; Krejsgaard T; Gniadecki R; Bonefeld CM; Skov L; Geisler C; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
    Cell Cycle; 2013 Jun; 12(12):1939-47. PubMed ID: 23676217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
    Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
    Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
    Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
    Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-155 meets the JAK/STAT pathway.
    Persson JL
    Cell Cycle; 2013 Jul; 12(14):2170. PubMed ID: 23803728
    [No Abstract]   [Full Text] [Related]  

  • 7. Keeping each other in check: a reciprocal relationship between cytokines and miRNA.
    Andersen MH
    Cell Cycle; 2013 Jul; 12(14):2171. PubMed ID: 23803727
    [No Abstract]   [Full Text] [Related]  

  • 8. Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.
    Ehrentraut S; Schneider B; Nagel S; Pommerenke C; Quentmeier H; Geffers R; Feist M; Kaufmann M; Meyer C; Kadin ME; Drexler HG; MacLeod RA
    Oncotarget; 2016 Jun; 7(23):34201-16. PubMed ID: 27144517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
    Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
    Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
    Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
    Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.
    Lauenborg B; Christensen L; Ralfkiaer U; Kopp KL; Jønson L; Dabelsteen S; Bonefeld CM; Geisler C; Gjerdrum LM; Zhang Q; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
    Oncotarget; 2015 Jun; 6(17):15235-49. PubMed ID: 25915535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
    Zhang Q; Nowak I; Vonderheid EC; Rook AH; Kadin ME; Nowell PC; Shaw LM; Wasik MA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9148-53. PubMed ID: 8799169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma.
    Abraham RM; Zhang Q; Odum N; Wasik MA
    Cancer Biol Ther; 2011 Dec; 12(12):1019-22. PubMed ID: 22236880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
    Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma.
    Shen X; Wang B; Li K; Wang L; Zhao X; Xue F; Shi R; Zheng J
    J Invest Dermatol; 2018 Sep; 138(9):2024-2032. PubMed ID: 29559342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.
    Bagdonaite I; Wandall HH; Litvinov IV; Nastasi C; Becker JC; Dabelsteen S; Geisler C; Bonefeld CM; Zhang Q; Wasik MA; Zhou Y; Sasseville D; Ødum N; Woetmann A
    Oncotarget; 2015 Jun; 6(16):14374-84. PubMed ID: 25957418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.
    Geskin LJ; Viragova S; Stolz DB; Fuschiotti P
    Blood; 2015 Apr; 125(18):2798-805. PubMed ID: 25628470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
    Yumeen S; Girardi M
    Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.